3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Ovarian Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Lung Neoplasms
2
Lethal Congenital Contracture Syndrome 2
2
Head and Neck Neoplasms
2
Fibromatosis, Gingival, 2
2
Fallopian Tube Neoplasms
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor Cancers
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Kidney Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Bile Duct Neoplasms
1
Adenocarcinoma
1
Interventions
Gemcitabine
22
Fluorouracil
14
Oxaliplatin
13
Capecitabine
13
Paclitaxel
12
pembrolizumab
11
Cisplatin
11
Carboplatin
11
Pemetrexed
10
Leucovorin
9
130-nm albumin-bound paclitaxel
9
Ramucirumab
8
zolbetuximab
7
Albumin-Bound Paclitaxel
7
trastuzumab deruxtecan
6
Drug Therapy
5
Docetaxel
5
Bevacizumab
5
Nivolumab
4
Irinotecan
4
vandetanib
3
cemiplimab
3
Everolimus
3
EC145
3
tislelizumab
2
technetium 99m etarfolatide
2
spartalizumab
2
pralsetinib
2
osimertinib
2
nimotuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenocarcinoma
×
seribantumab
×
Clear all
NCT02387216
2021-10-12
SHERLOC
Elevation Oncology
Phase 2
Terminated
153 enrolled
19 charts